Nowadays, the prevalence of neurodegenerative diseases (NDD) is increasing, in part due to modern living standards which extend life length and contribute to the world population's aging 1 . Among NDDs, Alzheimer's disease (AD) is the most notable form of dementia in the world, and the one that most affects the elderly 2 , making it a worldwide public health problem. Despite advances in medicine, which have decreased mortality rates resulting from this disease and improved quality-of-life in patients, AD is still one of the most damaging pathologies for this age group. AD is a prevalent neurodegenerative disorder affecting millions worldwide, presenting significant challenges in drug development due to its multifactorial nature. Current therapeutic strategies often target single pathways, which may not be sufficient to address the complexity of AD. By triggering multiple health threats, it leads to enormous healthcare system costs.